top of page
bpmed_logo(회사로고).png
final.pub.white.png

VECTOR

INSERT

pET21b

MTD 

~20 amino acid

Name : Clostridium botulinum neurotoxin type A light chain

Lc

Amino acid: 447 amino acid

Sequence : Clostridium botulinum type A Hall Lc

Tag

Hexa-histidine

OUR INGREDIENT

Structure of 'Methionyl r-Clostridium

Botulinum Polypeptide-1 Hexapeptide-40'

'Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40' is developed as recombination of peptide called “MTD” (Macro-molecule Transmission Domain) that has function of skin and target cell permeation and, active protein of botulinum toxin called 'Light Chain'.  'MTD' applied to our ingredient is originated and developed from botulinum toxin 'Heavy Chain', ,which performing a cell-penatration function of botulinum toxin. 

STRUCTURE

자산 6.png

MTD

Lc

His

469aa(53.6kDa)

COMPARISON IF BOTULINUM INGREDIENTS

Toxin Complex

(Medical Botox Injection)

ob 1.png

Botulinum Light Chain A

Botulinum Heavy Chain

Hemaggultinin

Non-toxin

Non-toxin Non-Hemagglutinin

Composition

Heavy chain : Nerve cell penetration

Light chain : Botulinum Efficacy Part

Hemagglutinin

Non-toxin Non-Hemagglutinin

Commercialization

1980

Example

BOTOX (Allergan, US)

MEDITOXIN (Meditox, Korea)

Not permitted to use in Cosmetic Product

Molecular weight

900KDa

Pure Toxin

(Medical Botox Injection)

ob 2.png

Botulinum Light Chain A

Botulinum Heavy Chain

Composition

Heavy chain : Nerve cell penetration

Light chain : Botulinum Efficacy Part

Commercialization

1995

Example

XEOMIN (Merz, Germany)

Not permitted to use in Cosmetic Product

Molecular weight

150KDa

Our Ingredient

(BPMed_BoLCA_Protein)

ob 3.png

Botulinum Light Chain A

MTD Protein

Composition

Light Chain + MTD

Botulinum Efficacy Part

Marco-molecule Transmission Domain

(Skin & Nerve cell penetration)

= Recombination of the Protein

Commercialization

2014

Example

BoLCA+ (BPMed cosmetic, Korea)

The First Botulinum Ingredient on ICID

BPMed Cosmetic has Exclusivity

Molecular weight

50KDa

SKIN AND CELL PENETRATION TECHNOLOGY OF MTD

Platform technology to improve transdermal delivery of 

'Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40'

1st Action

Improved penetration of functional materials into stratum corneum and other skin layers by MTD.

2nd Action

Maximized efficacy through the delivery of 'Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40' into specific targets.

ob 5.png

Epidermis

Dermis

Subcutaneous Tissue

Muscle Layer

Cell

ob 4.png

Cell

Macro-molecule Transmission Domain (MTD)

Cell-To-Cell Delivery

Modality of Intracellular delivery of MTD in 'Methionyl

r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40'

Permeate in to cell by MTD technology shows very high Permeability and significantly less cell damage then nano liposome or common peptide ingredients(PTD).

MECHANISM ON NERVE CELL

sc 8.png

Normal Neurotransmission Process

SNARE Complex Exocitosis Acetylcholine Diffusion

Binds to the Receptors on the Muscle

sc 4.png

Nerve Cell

Approaching to the Cell

sc 6.png

SNAP 25

Moves to the SNAP25 

sc 1.png

Penetrated in to dermis layer

Methionyl r-Clostridium Botulinum 

Polypeptide-1 Hexapeptide-40

sc 5.png

Direct Cell Membrane Translocation

sc 7.png

Cleaves SNAP25 by Light Chain Part

bottom of page